Efficacy and safety of XXXX , a new @entity2453 reductase inhibitor, in elderly hypercholesterolaemic @entity1 .

@entity1 @entity5470 @entity1674 @entity755 @entity412 @entity2453 @entity298 @entity165
This multicentre open 6-week study evaluated the efficacy, safety and tolerability of @entity5470 , the first fully synthetic @entity2453 ( @entity2453 ) reductase inhibitor, in elderly @entity1 with type IIa hypercholesterolaemia. After a 4-week single-blind placebo period, 22 elderly @entity1 (mean age 68 +/- 5 years) with @entity298 [low density lipoprotein (LDL) @entity165 > 160 mg/dl] were enrolled in the trial. @entity5470 40 mg was administered once in the evening. At baseline, and after 3 and 6 weeks of treatment, total @entity165 , LDL @entity165 , high density lipoprotein (HDL) @entity165 , @entity1674 , apolipoproteins B ( @entity755 ) and A-I (apo A-I) were measured. Safety and tolerability were assessed by monitoring routine laboratory parameters and by recording spontaneously reported side effects. The mean (+/- SD) baseline total @entity165 , LDL @entity165 , @entity412 , HDL @entity165 , @entity755 and apo A-I levels were 325 +/- 43, 236 +/- 43, 128 +/- 56, 61 +/- 16, 221 +/- 60 and 164 +/- 28 mg/dl, respectively. After 6 weeks, @entity5470 significantly (p < 0.001, ANOVA test) reduced total @entity165 , LDL @entity165 and @entity755 levels by 22%, 29% and 23%, respectively. These significant reductions were already reached at week 3 (total @entity165 , -21%; LDL @entity165 , -27%). The total @entity165 : HDL @entity165 ratio was reduced by 22% at week 3 and by 21% at week 6 (from 5.3 to 4.2). 78% of the @entity1 showed a reduction > or = 20% for LDL @entity165 . @entity1674 were reduced by 16% (not significant).(ABSTRACT TRUNCATED AT 250 WORDS)
